(A) The Mark I™ autoinjector, consisting of two antidotes to be used after exposures to a nerve or organophosphate agent in a disaster situation. The kit contains an atropine autoinjector (2 mg/0.7 mL) and a pralidoxime chloride (2-PAM) autoinjector (600 mg/2 mL). (B) The DuoDote™ autoinjector (replacing the Mark I™ autoinjector) contains 2.1 mg atropine and 600 mg of pralidoxime chloride in one syringe. Source: Chemical Threat Agent Exposure: Name That Poison Level II, Pharmacotherapy Casebook: A Patient-Focused Approach, 10e Citation: Schwinghammer TL, Koehler JM, Borchert JS, Slain D, Park SK. Pharmacotherapy Casebook: A Patient-Focused Approach, 10e; 2017 Available at: https://accesspharmacy.mhmedical.com/DownloadImage.aspx?image=/data/books/2047/pharmcase10_ch11_f001a.png&sec=155236622&BookID=2047&ChapterSecID=155236573&imagename= Accessed: October 17, 2017 Copyright © 2017 McGraw-Hill Education. All rights reserved